<DOC>
	<DOC>NCT00752427</DOC>
	<brief_summary>The purpose of this open-label study was to evaluate the safety and tolerability of flexible doses of Extended Release OROS® Paliperidone in the treatment of geriatric subjects with schizophrenia after completion of the initial double blind study</brief_summary>
	<brief_title>24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia</brief_title>
	<detailed_description>The primary objective of the open-label extension phase was the long-term assessment of safety and tolerability of Extended Release (ER) OROS paliperidone (3 mg to 12 mg/day) in subjects (&gt;65 years of age) with schizophrenia, and the secondary objective was the assessment of long-term efficacy. Paliperidone ER OROS® tablet formulation (3 to 12 mg/day) to be taken orally</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Subjects who had completed the doubleblind phase or discontinued due to lack of efficacy after at least 21 days of treatment, who signed the informed consent for the openlabel phase, and who the investigator agreed that openlabel treatment was in the best interest of the subject were eligible to participate in the open label phase Significant and/or unstable systemic illnesses Allergy or hypersensitivity to risperidone or paliperidone Significant risk of suicidal or violent behavior Biochemistry, hematology, or urinalysis results that are not within the laboratory's reference range, and that are deemed by the investigator to be clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia: paliperidone</keyword>
</DOC>